USDA data shows snack sales holding steady in 2024, even as GLP-1 weight loss drug use rises, highlighting shifting consumer ...
Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...
Two studies examining the use of glucagon-like peptide-1 receptor agonists, including semaglutide, have found short- and long-term associations in orthopedic postoperative outcomes and general ...
By Dennis Thompson HealthDay ReporterTHURSDAY, March 12, 2026 (HealthDay News) — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the ...
What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast ...
Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...
Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn't switch, according to ...
GLP-1 drugs have ushered in a new era in weight loss. In just a few years, medications such as semaglutide and tirzepatide, known by the brand names Ozempic, Wegovy, Mounjaro and Zepbound, have gone ...
Even though opioid overdoses reached their all-time peak in 2019, opioid prescriptions decreased by 37.1 percent from 2014-19, according to the most recent report from the American Medical Association ...
Obesity dipped in Minnesota as GLP‑1 use rose. Experts warn the long‑term picture and who pays are still unsettled.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results